BioSpace News Archive

Drug Development

First Patient Imaged in SOFIE’s FAPI Phase II trial

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [ 68 Ga]FAPI-46 at NYU Langone in its US Clinical Trial of Fibroblast Activation Protein Inhibitor (FAPI).

October 13, 2022
·
3 min read
Business

CCS Announces Innovative Partnership with Welldoc and ZeOmega Aimed at Helping People with Chronic Conditions Lead Healthier Lives while Reducing Healthcare Costs

CCS has announced a new technology partnership Welldoc and ZeOmega to expand its established LivingConnected® solution.

October 13, 2022
·
5 min read
Bio NC

STRONG-HF study in patients admitted for acute heart failure (HF) terminated early for superior efficacy

Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies) study, announced today the premature termination of the trial.

October 13, 2022
·
3 min read
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Relmada Therapeutics, Inc. today announced that its RELIANCE III study (REL-1017-303), evaluating REL-1017 in the monotherapy setting for Major Depressive Disorder (MDD).

October 13, 2022
·
6 min read
Genetown

Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Regresses Tumor Growth Without Toxicity

Genuv Inc. unveiled a new drug candidate, GNUV205, a fusion of engineered IL2 and anti-PD-1 antibody that advances immuno-oncology science.

October 13, 2022
·
3 min read
Genetown

Veristat Joins Decentralized Trials & Research Alliance (DTRA) to Improve the Patient Experience

Veristat announced that it has joined an alliance of over 120 life sciences and healthcare organizations whose mission is to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

October 13, 2022
·
4 min read
Business

Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022.

October 13, 2022
·
1 min read
Pharm Country

Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders

Sema4 (Nasdaq: SMFR), a health insights company, is presenting research today on autism spectrum disorders (ASD) at the Child Neurology Society (CNS) Annual Meeting.

October 13, 2022
·
2 min read
Biotech Bay

Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.

October 13, 2022
·
7 min read
BioForest

Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present data from the Company’s Phase 1 influenza A clinical trial with CC-42344 at the World Antiviral Congress 2022 on Friday, December 1, 2022 at 11:10 a.m. Pacific time.

October 13, 2022
·
2 min read